Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 9/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 3/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3588753 | 0.86 | BRD4 (0.50) | KDM4EALDH1A1SMN1; SMN2PDE3BPDE3A | |
| SCHEMBL89103 | 0.81 | KDM4E (0.56) | KDM4EALDH1A1SMN1; SMN2PDE3BPDE3A | |
| SCHEMBL445148 | 0.79 | KDM4E (0.58) | KDM4EALDH1A1SMN1; SMN2PDE3BPDE3A | |
| SCHEMBL295046 | 0.79 | KDM4E (0.58) | KDM4EALDH1A1SMN1; SMN2PDE3BPDE3A | |
| SCHEMBL29622749 | 0.79 | KDM4E (0.55) | KDM4EALDH1A1SMN1; SMN2PDE3BPDE3A | |
| SCHEMBL8256073 | 0.79 | KDM4E (0.55) | KDM4EALDH1A1SMN1; SMN2PDE3BPDE3A | |
| SCHEMBL1634782 | 0.79 | KDM4E (0.55) | KDM4EALDH1A1SMN1; SMN2PDE3BPDE3A | |
| SCHEMBL30024800 | 0.79 | KDM4E (0.55) | KDM4EALDH1A1SMN1; SMN2PDE3BPDE3A | |
| SCHEMBL30343148 | 0.79 | KDM4E (0.58) | KDM4EALDH1A1SMN1; SMN2PDE3BPDE3A | |
| SCHEMBL13545259 | 0.77 | KDM4E (0.56) | KDM4EALDH1A1SMN1; SMN2PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128157-A1 | HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | KDM4E 2284/4885ALDH1A1 1904/4885SMN1; SMN2 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.